Renal cell cancer is the most common type of kidney cancer and in Ireland 266 new cases and 140 cancer deaths are reported per year.1 It can be treated in a number of ways depending on the stage of the cancer and the patient's age and health, but thus far it has proved to be very resistant to chemotherapeutic drugs.
Dr Matthias Tacke, a Senior Lecturer at the UCD School of Chemistry and Chemical Biology and a researcher with the Centre for Synthesis and Chemical Biology has been working on known anti-cancer drugs belonging to the titanocene family for five years.
Dr Matthias Tacke with his CSCB research group
